For the quarter ending 2026-03-31, INKT has $10,376,972 in assets. $9,525,676 in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 9,525,676 | 13,360,340 | 14,281,212 | 1,681,915 |
| Prepaid expenses | 264,521 | 276,431 | 253,077 | 274,079 |
| Other current assets | 232,257 | 211,202 | 32 | 55,208 |
| Total current assets | 10,022,454 | 13,847,973 | 14,534,321 | 2,011,202 |
| Equipment, net of accumulated depreciation of 647,801 and 612,245 at march 31, 2026 and december 31, 2025, respectively | 354,518 | 390,869 | 429,344 | 473,215 |
| Total assets | 10,376,972 | 14,238,842 | 14,963,665 | 2,484,417 |
| Accounts payable | 3,391,418 | 3,425,314 | 3,693,115 | 3,314,839 |
| Accrued liabilities | 1,326,265 | 1,579,147 | 1,256,965 | 1,861,464 |
| Related party note | 0 | 5,179,444 | 5,725,267 | 5,506,346 |
| Other current liabilities | 2,569,742 | 2,847,543 | 2,758,207 | 2,480,916 |
| Total current liabilities | 7,287,425 | 13,031,448 | 13,433,554 | 13,163,565 |
| Related party note | - | - | 0 | 0 |
| Due to related parties | 15,775,536 | 15,435,053 | 15,043,093 | 14,510,167 |
| Common stock, par value 0.00001 per share 150,000,000 shares authorized 4,968,794 and 4,706,246 shares issued at march 31, 2026 and december 31, 2025, respectively | 51 | 48 | 46 | 40 |
| Additional paid-in capital | 147,429,749 | 143,167,204 | 141,252,978 | 126,716,146 |
| Accumulated other comprehensive loss | -697,426 | -718,916 | -692,114 | -719,318 |
| Accumulated deficit | -159,418,363 | -156,675,995 | -154,073,892 | -151,186,183 |
| Total stockholders' deficit | -12,685,989 | -14,227,659 | -13,512,982 | -25,189,315 |
| Total liabilities and stockholders' deficit | 10,376,972 | 14,238,842 | 14,963,665 | 2,484,417 |
MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics, Inc. (INKT)